A profitable new definition of health

Journal of Consumer Marketing - Tập 24 Số 1 - Trang 5-7 - 2007
Susan W.Myers1, MarlaRoyne Stafford1
1Department of Marketing and Supply Chain Management, Fogelman College of Business, University of Memphis, Memphis, USA

Tóm tắt

PurposeThe purpose of this article is to question pharmaceutical companies in their efforts to define the problems for which they are providing solutions. It addresses the impact of DTC advertising in making drug companies one of the most profitable industries in the country and how these profits can influence marketing decisions that leave consumers vulnerable.Design/methodology/approachThis article identifies some possible conflicts of interests in the pharmaceutical industry.FindingsMarketing practices of the drug companies are shaping consumers' definitions of health through the expansion of medical definitions and potential markets followed by the mass advertising of these messages. Other conflicts of interests between academic medicine and the pharmaceutical industry also exist with for‐profit sponsorship of medical research compromising the impartiality of the researchers.Practical implicationsWhen discussing public policy issues related to DTC advertising, it is important to look beyond the characteristics of the messages themselves and understand the foundations on which they are built before determining the benefits or harm that result.Originality/valueQuestioning the intentions of the drug companies and the other players in pharmaceutical marketing is the only way to ensure that consumer interests are protected.

Từ khóa


Tài liệu tham khảo

American Psychiatric Association (2000), “FDA recognition of PMDD reawakens controversy“, Psychiatric News, August 18, available at: www.psych.org/pnews/00‐08‐18/fda.html (accessed March 9, 2006).

Angell, M. (2000), “Is academic medicine for sale”, New England Journal of Medicine, Vol. 342 No. 20, pp. 1516‐8.

Bodenheimer, T. (2000), “Uneasy alliance – clinical investigators and the pharmaceutical industry”, New England Journal of Medicine, Vol. 342 No. 20, pp. 1539‐44.

Decoster, G. (1999), “Clinical research after drug approval: what is needed and what is not”, Drug Information Journal, Vol. 33, April‐June, pp. 627‐34.

Kravitz, R.L., Epstein, R.M., Feldman, M.D., Franz, C.E., Azari, R., Wilkes, M.S., Hinton, L. and Franks, P. (2005), “Influence of patients' requests for direct‐to‐consumer advertised antidepressants”, The Journal of the American Medical Association, Vol. 293 No. 16, pp. 1995‐2002.

Loe, M. (2004), The Rise of Viagra: How the Little Blue Pill Changed Sex in America, New York University Press, New York, NY.

National Center for Health Statistics (2005), “Health, United States, 2005”, available at: www.cdc.gov/nchs/data/hus/hus05.pdf (accessed March 9, 2006).

National Institute of Mental Health (2005), “Antidepressant medications for children and adolescents: information for parents and caregivers”, available at: www.nimh.nih.gov/healthinformation/antidepressant_child.cfm (accessed March 9, 2006).

Thomaselli, R. (2005), “FDA wedged between a rock and a hard place in DTC debate”, Advertising Age, Vol. 76 No. 45, pp. 1‐2.

Thông tin
Thông tin xuất bản

Journal of Consumer Marketing

Tập 24 Số 1

5-7

Thông tin tác giả